secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046109
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M
------------------------------------------------------------------------------

- Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.
- Net loss $13.8M ($0.53/share) vs $22.2M ($1.04) in Q1 2024; cash $102.7M.
- FY2025 revenue guidance $55-58M; Q2 revenue expected $13-14M.
- Active U.S. implanting centers 227 (+19% YoY); gross margin 84%.
- Real-world evidence: 85% reduction in HF hospital visits (Premier Healthcare Database).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/0001104659-25-046109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465925046109/tm2514410d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer